CRISPR-Cas9 Emerges as Promising Tool for Treating Blood Disorders

Published in Cytotherapy Volume 25, Issue 3 (March 2023)

A recent review in Cytotherapy highlights how CRISPR-Cas9 gene editing is transforming the treatment landscape for inherited blood disorders. By targeting hematopoietic stem and progenitor cells, researchers are developing novel therapies for diseases like SCID, CGD, Fanconi anemia, and Wiskott–Aldrich syndrome. Advances also extend into cancer immunotherapy, with applications in CAR-T and oncolytic virus strategies. While delivery into stem cells remains a technical hurdle, several approaches reviewed are already advancing into clinical stages with encouraging early outcomes.

Read the full article in Cytotherapy:

👉 CRISPR/Cas9-mediated gene editing: A promising strategy in hematological disorders

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.